BYND Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BYND is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is trading under $1 after a sharp drop, but the move is being driven by weakening fundamentals, missed revenue expectations, a poor outlook, and repeated analyst target cuts. For an impatient investor who does not want to wait for a better entry, this is still not an attractive long-term purchase today.
The trend is weak and remains negative. MACD histogram is below zero and still expanding negatively, which supports downside momentum. RSI at 46.23 is neutral, so there is no oversold recovery signal yet. Moving averages are converging, suggesting indecision, but price action is sitting below the pivot at 0.944 and closer to support at 0.836 than resistance at 1.053. The recent price change of -14.15% regular session also confirms strong bearish pressure. Overall, the technical setup does not support a buy.
Recent news includes a restructuring plan, a new beverage product launch, and exit from the Chinese market, which could help simplify operations over time. Options positioning shows relatively low put-call ratios, suggesting some traders are still leaning bullish. The stock trend model also shows a modest next-month rebound probability, but this is not strong enough to change the overall view.
Q1 revenue fell 15.3% year over year to $58.2M, net income worsened, EPS remained negative, and gross margin was extremely weak. Q2 revenue guidance of $60M-$65M missed consensus, signaling continued demand problems. Analysts are repeatedly cutting price targets and maintaining Sell/Underperform/Underweight views. Insiders are selling heavily, with selling up 58,430.79% over the last month. Hedge funds are neutral, and there is no supportive congress or politician trading data.
In Q1 2026, Beyond Meat showed deteriorating fundamentals: revenue declined 15.31% YoY to $58.2M, net income dropped to -$28.48M, EPS fell to -$0.06, and gross margin collapsed to 4.35%. This indicates shrinking sales, persistent losses, and poor profitability. The latest quarter season is Q1 2026, and the following quarter outlook is also weak, with Q2 revenue guidance below expectations.
Analyst sentiment is bearish and getting worse. TD Cowen cut its target to $0.60 and kept Sell; Mizuho cut to $0.50 and kept Underperform; BMO cut to $1.00 and kept Market Perform; Barclays cut to $0.50 and kept Underweight; Jefferies cut to $0.70 and kept Hold. The overall Wall Street view is that sales are weak, margins are under pressure, visibility is limited, and the recovery story is not convincing. Pros are limited to cost control, restructuring efforts, and product diversification. Cons dominate: falling sales volumes, poor Q1 results, weak Q2 guidance, and continued category weakness.
